- Home
- AI vs MRUS Comparison
AI vs MRUS Comparison
Compare AI & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AI
- MRUS
- Stock Information
- Founded
- AI 2009
- MRUS 2003
- Country
- AI United States
- MRUS Netherlands
- Employees
- AI N/A
- MRUS N/A
- Industry
- AI Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- AI Technology
- MRUS Health Care
- Exchange
- AI Nasdaq
- MRUS Nasdaq
- Market Cap
- AI 2.9B
- MRUS 2.7B
- IPO Year
- AI 2020
- MRUS 2016
- Fundamental
- Price
- AI $23.37
- MRUS $40.90
- Analyst Decision
- AI Hold
- MRUS Strong Buy
- Analyst Count
- AI 14
- MRUS 14
- Target Price
- AI $30.15
- MRUS $87.00
- AVG Volume (30 Days)
- AI 3.0M
- MRUS 778.1K
- Earning Date
- AI 05-28-2025
- MRUS 05-07-2025
- Dividend Yield
- AI N/A
- MRUS N/A
- EPS Growth
- AI N/A
- MRUS N/A
- EPS
- AI N/A
- MRUS N/A
- Revenue
- AI $366,923,000.00
- MRUS $54,732,000.00
- Revenue This Year
- AI $28.93
- MRUS $26.81
- Revenue Next Year
- AI $21.50
- MRUS $23.85
- P/E Ratio
- AI N/A
- MRUS N/A
- Revenue Growth
- AI 23.79
- MRUS 42.77
- 52 Week Low
- AI $17.03
- MRUS $33.19
- 52 Week High
- AI $45.08
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- AI 60.03
- MRUS 45.06
- Support Level
- AI $21.23
- MRUS $37.92
- Resistance Level
- AI $22.71
- MRUS $46.36
- Average True Range (ATR)
- AI 0.86
- MRUS 2.58
- MACD
- AI 0.33
- MRUS -0.27
- Stochastic Oscillator
- AI 85.62
- MRUS 35.31
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.